

Clinical Update

Priyanka Saxena, D.O., CDPH

COVID-19 Vaccine Safety Data

- CDC and FDA continuing to analyze data regarding co-administration of mRNA bivalent booster and flu vaccine
- Consulting with other surveillance systems to understand:
 - Possible role of simultaneous high-dose or adjuvanted flu vaccine with COVID-19 vaccine
 - Possible decreased rate of stroke in 3-6 weeks post-vaccination
- CDC continues to recommend everyone that is eligible for a COVID-19 mRNA bivalent booster or flu vaccine get vaccinated

COVID-19 Bivalent Booster Vaccine Effectiveness Summary

- Provides added protection against **symptomatic infection** in individuals 5 years of age and older
 - Early evidence of waning of relative VE
- Provides added protection against **ED/UC visits and hospitalizations** in adults 18 years of age and older

Policy considerations for bivalent primary series

- Policy on bivalent primary series will be coordinated with **FDA** for regulatory action, and **CDC/ACIP** for recommendations for use



CDC Workgroup Considerations for Future Planning

- Simplify COVID-19 vaccine recommendations
 - Improve communication
 - Reduce barrier to vaccination
- Continue to discuss ideal dose and timing
- Supportive of Fall/annual COVID-19 vaccine program
 - Ongoing reviews of bivalent booster VE & safety data
 - Cost effectiveness analyses
 - COVID-19 epidemiology, genomic surveillance, virus evolution

Preliminary 2022-2023 Influenza Vaccine Effectiveness

- Data through January 2023
- Pediatrics: New Vaccine Surveillance Network (NVSN)
 - Vaccine effectiveness against lab-confirmed influenza A
 - 68% (95% CI: 46, 81) against pediatric hospitalizations
 - 42% (95% CI: 25, 56) against pediatric ED visits
- Adults: Investigating Respiratory Viruses in the Acutely Ill (IVY Network)
 - 43% (95% CI: 30, 54) against adult hospitalizations